Mekan R. Orazov , Viktor E. Radzinsky , Evgeny D. Dolgov
Abstract
Polycystic ovary syndrome is a proven risk factor for both endometrial hyperplasia and cancer. The article reflects the current paradigm of etiology, pathogenesis and management of patients with endometrial hyperplasia on the background of polycystic ovary syndrome, according to the data of domestic and foreign literature.
Keywords: endometrial hyperplasia, polycystic ovary syndrome, endometrial cancer, gestagens, myo-inositol.
About the Author
Mekan R. Orazov 1 , Viktor E. Radzinsky 1 , Evgeny D. Dolgov 11 People’s Friendship University of Russia (RUDN University), Moscow, Russia
References
1. Obesity Rates by Country 2024. [Electronic resource]. URL:
2. Boutari C, Mantzoros CS. A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism. 2022;133:155217. DOI: 10.1016/j.metabol.2022.155217
3. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12-49. DOI: 10.3322/caac.21820. Epub 2024 Jan 17. Erratum in: CA Cancer J Clin. 2024;74(2):203. PMID: 38230766.
4. Kokts-Porietis RL et al. Prospective cohort of pre-and post-diagnosis alcohol consumption and cigarette smoking on survival outcomes: an Alberta Endometrial Cancer Cohort Study. Cancer Causes & Control. 2024;35(1):121-32.
5. Lee-may Chen et al. Endometrial carcinoma: Epidemiology, risk factors, and prevention. UpToDate. 2024;Feb 16.
6. Power RF et al. Modifiable Risk Factors and Risk of Colorectal and Endometrial Cancers in Lynch Syndrome: A Systematic Review and Meta-Analysis. JCO Precision Oncology. 2024;8:e2300196.
7. Witchel SF, Oberfield SE, Peña AS. Polycystic ovary syndrome: pathophysiology, presentation, and treatment with emphasis on adolescent girls. Journal of the Endocrine Society. 2019;3(8):1545-73.
8. Fearnley EJ, Marquart L, Spurdle AB, Weinstein P et al. Polycystic ovary syndrome increases the risk of endometrial cancer in women aged less than 50 years: an Australian case-control study. Cancer Causes Control. 2010;21(12):2303-8
9. Indhavivadhana S, Rattanachaiyanont M, Wongwananuruk T et al. Endometrial neoplasia in reproductive-aged Thai women with polycystic ovary syndrome. Int J Gynecol Obstet. 2018;142(2):170-5.
10. Yin W, Falconer H, Yin L et al. Association between polycystic ovary syndrome and cancer risk. JAMA Oncol. 2019;5(1):106-7.
11. Meczekalski B, Perez-Roncero GR, Lopez-Baena MT et al. The polycystic ovary syndrome and gynecological cancer risk. Gynecol Endocrinol. 2020;36(4):289-93.
12. Johnson JE, Daley D, Tarta C, Stanciu PI. Risk of endometrial cancer in patients with polycystic ovarian syndrome: A meta-analysis. Oncology Letters. 2023;25(4):1-9.
13. Bril F, Ezeh U, Amiri M et al. Adipose tissue dysfunction in polycystic ovary syndrome. J Clin Endocrinol Metab. 2024;109(1):10-24.
14. Patel BG, Rudnicki M, Yu J et al. Progesterone resistance in endometriosis: origins, consequences and interventions. Acta Obstet Gynecol Scand. 2017;96:623-32. DOI: 10.1111/aogs.13156
15. Fernandez-Montoli M-E, Sabadell J, Contreras-Perez N-A. Fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer: a cochrane systematic review protocol. Adv Ther. 2021;38:2717-31. DOI: 10.1007/s12325-021-01693-y
16. Kliemann N, Viallon V, Murphy N et al. Metabolic signatures of greater body size and their associations with risk of colorectal and endometrial cancers in the European prospective investigation into cancer and nutrition. BMC Med. 2021;19:101. DOI: 10.1186/s12916-021-01970-1
17. Yang HP, Meeker A, Guido R et al. PTEN expression in benign human endometrial tissue and cancer in relation to endometrial cancer risk factors. Cancer Causes Control. 2015.26:, 1729-36. DOI: 10.1007/s10552-015-0666-5
18. Lv Q, Xie L, Cheng Y et al. A20-mediated deubiquitination of ERα in the microenvironment of CD163+ macrophages sensitizes endometrial cancer cells to estrogen. Cancer Lett. 2019;442:137-47. DOI: 10.1016/j.canlet.2018.10.019
19. Byrne FL, Martin AR, Kosasih M et al. The role of hyperglycemia in endometrial cancer pathogenesis. Cancers. 2020;12:1191. DOI: 10.3390/cancers12051191
20. Kolano A, Pejas A, Markowiak S et al. The Impact of Obesity on Endometrial Cancer: A Comprehensive Analysis. J Education Health Sport. 2024;51:179-97.
21. Wal A et al. Role of inflammation, oxidative stress, and angiogenesis in polycystic ovary syndrome (PCOS): Current perspectives. Targeting Angiogenesis, Inflammation, and Oxidative Stress in Chronic Diseases. 2024:459-85. DOI: 10.1016/B978-0-443-13587-3.00018-7
22. Dadachanji R, Shaikh N, Mukherjee S. Genetic variants associated with hyperandrogenemia in PCOS pathophysiology. Genetics Research International. 2018. DOI: 10.1155/2018/7624932
23. Yoo J-Y, Kang H-B, Broaddus RR et al. MIG-6 suppresses endometrial epithelial cell proliferation by inhibiting phospho-AKT. BMC Cancer. 2018;18:605. DOI: 10.1186/s12885-018-4502-7
24. Kara M, Ozcan SS, Aran T et al. Evaluation of endometrial receptivity by measuring HOXA-10, HOXA-11, and leukemia inhibitory factor expression in patients with polycystic ovary syndrome. Gynecology and minimally invasive therapy. 2019;8(3):118-22.
25. He B, Ni Z-L, Kong S-B et al. Homeobox genes for embryo implantation: from mouse to human. Animal Models Exp Med 2018;1:14-22. DOI: 10.1002/ame2.12002
26. Оразов М.Р., Радзинский В.Е., Хамошина М.Б. и др. Metabesity – патогенетические основы и возможности предикции. Гинекология. 2023;25(4). DOI: 10.26442/20795696.2023.4.202520 Orazov M.R., Radzinsky V.E., Khamoshina M.B. et al. Metabesity – pathogenetic foundations and possibilities of prediction. Gynecology. 2023;25(4). DOI: 10.26442/20795696.2023.4.202520 (in Russian).
27. Cocomazzi G, Del Pup L, Contu V et al. Gynecological Cancers and Microbiota Dynamics: Insights into Pathogenesis and Therapy. Int J Molecular Sciences. 2024;25(4);2237.
28. Mitchell CM, Haick A, Nkwopara E et al. Colonization of the upper genital tract by vaginal bacterial species in nonpregnant women. Am J Obstetric Gyn. 2015;212(5):611-e1.
29. Moreno I, Codoñer FM, Vilella F et al. Evidence that the endometrial microbiota has an effect on implantation success or failure. Am J Obstetric Gyn. 2016;215(6):684-703.
30. Carosso A, Revelli A, Gennarelli G. Controlled ovarian stimulation and progesterone supplementation affect vaginal and endometrial microbiota in IVF cycles: a pilot study. J Assist Reproduct Gen. 2020;37:2315-26.
31. Walther-António MR, Chen J, Multinu F et al. Potential contribution of the uterine microbiome in the development of endometrial cancer. Genome Med. 2016;8:122.
32. Гиперплазия эндометрия. Федеральные клинические рекомендации. М., 2021. Endometrial hyperplasia. Federal Clinical Guidelines. Moscow, 2021 (in Russian).
33. Classification and Management of Endometrial Hyperplasia. Erratum to Guideline No. 390. Journal of Obstetrics and Gynaecology Canada. 2019;42(10):1789-1800.
34. Singh G, Puckett Y. Endometrial Hyperplasia. [Updated 2023 Jul 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2023. URL: https://www.ncbi.nlm.nih.gov/books/NBK560693/
35. Chandra V, Kim JJ, Benbrook et al. Therapeutic options for management of endometrial hyperplasia. J Gynecol Oncol. 2016;27(1).
36. Nooh AM, Abdeldayem HM, Girbash EF. Depo-Provera versus norethisterone acetate in management of endometrial hyperplasia without atypia. Reproductive Sciences. 2016;23(4):448-54.
37. Vereide AB, Arnes M, Straume B et al. Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol. 2003; 91:526-33.
38. Güven M, Dikmen Y, Terek MC et al. Metabolic effects associated with high-dose continuous megestrol acetate administration in the treatment of endometrial pathology. Arch Gynecol Obstet. 2001; 265:183-6.
39. Gal D, Edman CD, Vellios F, Forney JP. Long-term effect of megestrol acetate in the treatment of endometrial hyperplasia. Am J Obstet Gynecol. 1983;146:316-22.
40. Brun JL, Belaisch J, Rivel J, Hocké C. Endometrial hyperplasias resistant to progestins: alternatives to traditional treatments. Gynecol Obstet Fertil. 2002;30:244-51.
41. Оразов М.Р., Радзинский В.Е., Хамошина М.Б. и др. Рецидивирующая гиперплазия эндометрия без атипии: как не попасть в порочный круг? Клинический разбор в общей медицине. 2023;4(9):21-30. DOI: 10.47407/kr2023.4.9.00324 Orazov M.R., Radzinsky V.E., Khamoshina M.B. et al. Recurrent endometrial hyperplasia without atypia: how to avoid falling into a vicious circle? Clinical review for general practice. 2023;4(9):21-30. DOI: 10.47407/kr2023.4.9.00324 (in Russian).
42. Синдром поликистоза яичников. Федеральные клинические рекомендации. М., 2021. Polycystic ovarian syndrome. Federal Clinical Guidelines. Moscow, 2021 (in Russian).
43. International evidence-based guideline for the assessment and management of polycystic ovary syndrome (PCOS). ESHRE, 2023.
44. Baker-Rand H, Kitson SJ. Recent Advances in Endometrial Cancer Prevention, Early Diagnosis and Treatment. Cancers. 2024;16(5):1028.
45. Lv Z, Guo Y. Metformin and its benefits for various diseases. Frontiers in endocrinology. 2020;11:490991.
46. Mellonie P, Manivannan A, Thangaraj P, Logeswari BM. The Effectiveness of Myo-Inositol in Women With Polycystic Ovary Syndrome: A Prospective Clinical Study. Cureus. 2024;16(2).
47. Greff D, Juhász AE, Váncsa S et al. Inositol is an effective and safe treatment in polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials. Reproductive Biology and Endocrinology. 2023;21(1):10.
48. Laganà AS, Myers, SH, Forte G et al. Inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: now and the future. Expert Opinion on Drug Metabolism & Toxicology. 2024:1-12.
49. Raj P, Samal, S, Chandrasekaran S et al. Comparison of Metformin and Myoinositol on Clinical, Hormonal and Metabolic Profile of Patients with Polycystic Ovarian Syndrome: An Open-label Randomised Clinical Trial. Journal of Clinical & Diagnostic Research. 2024;18(1).
50. Хурасева А.Б., Святченко К.С., Медведева И.Н. Новые возможности в лечении синдрома поликистозных яичников. Медицинский алфавит. 2022;(4):27-30. Khuraseva A.B., Svyatchenko K.S., Medvedeva I.N. New possibilities in the treatment of polycystic ovary syndrome. Medical Alphabet. 2022;(4):27-30 (in Russian).
51. Iversen L, Fielding S, Lidegaard Ø, Hannaford PC. Contemporary hormonal contraception and risk of endometrial cancer in women younger than age 50: a retrospective cohort study of Danish women. Contraception. 2020;102(3):152-8.
52. He Y, Wang J, Wang Y et al. Maintenance Therapy Can Improve the Oncologic Prognosis and Obstetrical Outcome of Patients With Atypical Endometrial Hyperplasia and Endometrial Cancer After Fertility-Preserving Treatment: A Multicenter Retrospective Study. Frontiers in Oncology. 2021;11:808881.
53. Wang Y, Nisenblat V, Tao L et al. Combined estrogen-progestin pill is a safe and effective option for endometrial hyperplasia without atypia: a three-year single center experience. J Gynecol Oncol. 2019; 30(3).
54. Montanino Oliva M et al. Effects of myo-inositol plus alpha-lactalbumin in myo-inositol-resistant PCOS women. J Ovarian Res. 2018;11: 38. DOI: 10.1186/s13048-018-0411-2
55. Gerli S, Papaleo E, Ferrari A, Di Renzo GC. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci. 2007;11(5):347-54.
56. Kamenov Z, Kolarov G, Gateva A et al. Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance. Gynecol Endocrinol. 2015;31(2):131-5
57. Iuorno M, Jakubowicz D, Baillargeon J-P et al. Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract. 2002 Nov-Dec;8(6):417-23. DOI: 10.4158/EP.8.6.417
58. Garzon S, Laganà AS, Monastra G. Risk of reduced intestinal absorption of myo-inositol caused by D-chiro-inositol or by glucose transporter inhibitors. Expert Opinion on Drug Metabolism & Toxicology. 2019. DOI: 10.1080/17425255.2019.1651839
59. Lepore E, Lauretta R, Bianchini M et al. Inositols Depletion and Resistance: Principal Mechanisms and Therapeutic Strategies. Int J Mol Sci. 2021;22:6796. DOI: 10.3390/ijms22136796
60. Carlomagno G, Unfer V. Inositol safety: Clinical evidences. Eur Rev Med Pharm Sci. 2011;15:931-6.
61. Lepore E, Lauretta R, Bianchini M et al. Inositols depletion and resistance: Principal mechanisms and therapeutic strategies. Int J Molecular Sciences. 2021;22(13):6796.
62. Monastra G, Sambuy Y, Ferruzza S et al. Alpha-lactalbumin Effect on Myo-inositol Intestinal Absorption: In vivo and In vitro. Curr Drug Deliv. 2018;15(9):1305-11.
63. Montanino Oliva M et al. Effects of myo-inositol plus alpha-lactalbumin in myo-inositol-resistant PCOS women. J Ovarian Res. 2018;11:38. DOI: 10.1186/s13048-018-0411-2
For citation:Orazov M.R., Radzinsky V.E., Dolgov E.D. "Ringed by fate". Carcinogenic risks in patients with polycystic ovary syndrome. Clinical review for general practice. 2024; 5 (3): 54–62. (In Russ.). DOI: 10.47407/kr2023.5.3.00374
All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
